Nuvalent saw the highest growth of 2.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 2.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Nuvalent’s patent filings and grants. Buy the databook here.
Nuvalent has been focused on protecting inventions in Australia(AU) with two publications in Q2 2024
The Australia(AU) Patent Office dominates the patent filings with nearly 40% of filings. The Australia(AU), Israel(IL), World Intellectual Property Organization(WIPO), and European Patent Office(EPO) patent Office are among the top ten patent offices where Nuvalent is filings its patents..
Roche and Johnson & Johnson could be the strongest competitors for Nuvalent
Solid tumor related patents lead Nuvalent portfolio
Nuvalent has highest number of patents in solid tumor.
For comprehensive analysis of Nuvalent's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.